Inhibition of p450 17 as a new strategy for the treatment of prostate cancer.
The cytochrome P450 monooxygenase enzyme system is involved in the synthesis and/or degradation of a large number of endogenous compounds and in the biotransformation of drugs and other xenobiotics. 17alpha-Hydroxylase-C17,20-lyase (P450 17, CYP 17) is the key enzyme of the androgen biosynthesis. As androgens have been implicated in the development and progression of prostate cancer, this enzyme has become a promising therapeutic target. This paper will review the possible approaches dealing with P450 17 inhibition as a chemotherapeutic strategy in the struggle against prostate cancer.
Leroux
F
F
Laboratoire de Stéréochimie associé au CNRS (UMR CNRS 7509), Université Louis Pasteur (ECPM), Strasbourg, France. lerouxf@ecpm.u-strasbg.fr
D000726:Androgen Antagonists / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D000736:Androstenes; D000737:Androstenols / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use; D020128:Inhibitory Concentration 50; D008297:Male; D015394:Molecular Structure; D011471:Prostatic Neoplasms / Q000188:drug therapy* / Q000201:enzymology; D013254:Steroid 17-alpha-Hydroxylase / Q000037:antagonists & inhibitors* / Q000378:metabolism
D000726:Androgen Antagonists; D000736:Androstenes; D000737:Androstenols; D004791:Enzyme Inhibitors; D007093:Imidazoles; D013254:Steroid 17-alpha-Hydroxylase; C089740:abiraterone; C061121:liarozole